Sia/LBG

Latham BioPharm Group (LBG), part of Sia Partners, is a leading life sciences consulting company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies to solve complex business, regulatory, and product development challenges. Our experienced consultants come from large pharmaceutical companies, small biotechs, academia, and global CROs/CDMOs, and many have even held senior positions with government agencies. Since our founding in 1996, we have grown steadily and have built a robust capability set that has enabled us to help life sciences companies of various sizes drive long-term value into their organizations. In 2022, we became part of Sia Partners when they launched a division dedicated to life sciences consulting—a mutually beneficial merger that will open new doors as we look towards the future. Our core services include: • Product Development • Non-dilutive Funding • Strategic Consulting We are guided by value, both in our business model and in our industry-leading consulting. Our approach is scalable, flexible, and client-centric. We regard you as a partner and become a trusted part of your team. We adapt to your processes and align with your strategic direction and company objectives to generate meaningful analysis and quantifiable results. Both global organizations and emerging start-ups rely on us to guide their products and portfolios down a clear path to success. Sia Partners Sia Partners is a next-generation management consulting firm and pioneer of Consulting 4.0. We offer a unique blend of AI and design capabilities, augmenting traditional consulting to deliver superior value to our clients. With expertise in more than 30 sectors and services, we optimize client projects worldwide. Through our Consulting for Good approach, we strive for next-level impact by developing innovative CSR solutions for our clients, making sustainability a lever for profitable transformation.